| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10742370 | Journal of Geriatric Oncology | 2015 | 8 Pages |
Abstract
To our knowledge, our population of elderly patients treated with adjuvant trastuzumab is the largest analyzed so far. The beneficial long-term results were comparable to those in the younger cohorts. Although the risk of cardiotoxicity increased significantly with age, it also remained manageable in older patients. Thus, chronological age alone should not preclude HER2 antibody treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Peter Dall, Gertrud Lenzen, Thomas Göhler, Christian Lerchenmüller, Gabriele Feisel-Schwickardi, Thorsten Koch, Jochen Eggert, Volker Heilmann, Christof Schindler, Jochen Wilke, Hans Tesch, Johannes Selbach, Tim Wohlfarth, Heidi Eustermann, Axel Hinke,